A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis

NCT ID: NCT05153148

Last Updated: 2024-05-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 305 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-01-06
• Study Completion Date: 2023-06-02

Brief Summary

This study is designed to evaluate the efficacy, safety, and tolerability of NDI-034858 in participants with active Psoriatic Arthritis (PsA).

Detailed Description

This is a Phase 2b, Randomized, Multi-center, Double-Blind, Placebo-Controlled, Multiple Dose Study.

Randomization to one of the treatments with NDI-034858 Dose 1, 2, 3 or placebo once daily (QD) will be based on a 1:1:1:1 scheme.

The maximum study duration per participant is approximately 20 weeks, including up to 30 days for the screening period, a 12-week treatment period, and a 4-week safety follow-up period.

Efficacy will be assessed using the ACR20 composite measure (including tender and swollen joint count, patient assessment of PsA pain visual analog scale (VAS), patient global PsA assessment VAS, physician global PsA assessment, HAQ-DI, and hsCRP) as well as the additional components. Efficacy for psoriasis among participants who have ≥ 3% BSA) involvement on Day 1, will be measured using PASI, PGAs, and BSA.

Safety will be assessed by collecting AEs, recording vital signs, performing physical examinations, and evaluating clinical laboratory and ECGs results.

Blood samples will be collected to measure plasma concentrations of NDI-034858.

Conditions

Psoriatic Arthritis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Placebo

Participants received placebo capsules, orally, QD for 12 weeks.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

NDI-034858-matching oral placebo capsule

NDI-034858 Low Dose

Participants received NDI-034858 low dose, capsules, orally, QD for 12 weeks.

Group Type: EXPERIMENTAL

NDI-034858

Intervention Type: DRUG

NDI-034858 oral capsule

NDI-034858 Medium Dose

Participants received NDI-034858 medium dose, capsules, orally, QD for 12 weeks.

Group Type: EXPERIMENTAL

NDI-034858

Intervention Type: DRUG

NDI-034858 oral capsule

NDI-034858 High Dose

Participants received NDI-034858 high dose, capsules, orally, QD for 12 weeks.

Group Type: EXPERIMENTAL

NDI-034858

Intervention Type: DRUG

NDI-034858 oral capsule

Interventions

NDI-034858

NDI-034858 oral capsule

Intervention Type: DRUG

Placebo

NDI-034858-matching oral placebo capsule

Intervention Type: OTHER

Other Intervention Names

TAK-279

Eligibility Criteria

Inclusion Criteria

• Participant has PsA on the basis of the Classification Criteria for Psoriatic Arthritis with peripheral symptoms at the screening visit.
• Participant has a history of PsA symptoms for ≥ 6 months prior to the screening visit.
• Participant has ≥ 3 tender joints and ≥ 3 swollen joints at screening and Day 1 visits.
• Participant has at least one lesion of plaque psoriasis ≥ 2 cm in diameter, nail changes characteristic of psoriasis, or a documented history of plaque psoriasis.
• Participant has active PsA despite previous standard doses of non-steroidal anti-inflammatory drug (NSAIDs) administered for ≥ 4 weeks, or traditional disease-modifying anti-rheumatic drug (DMARDs) (including methotrexate and sulfasalazine) administered for ≥ 3 months, or tumor necrosis factor inhibitor (TNFi) agents administered for ≥ 3 months, or participants are intolerant to NSAIDs or DMARDs or TNFi agents.
• If participant is on concurrent PsA treatments, they must be on stable doses.
• All female participants should followed the protocol defined contraceptive method.

Exclusion Criteria

• Participant has other disease(s) that might confound the evaluations of benefit of NDI-034858 therapy, including but not limited to rheumatoid arthritis (RA), axial spondyloarthritis (this does not include a primary diagnosis of PsA with spondylitis), systemic lupus erythematosus, Lyme disease, or fibromyalgia.
• Participant has a history of lack of response to any therapeutic agent targeting IL-12, IL17, and/or IL23 at approved doses after at least 12 weeks of therapy, and/or received one of these therapies within 6 months prior to baseline (Day 1).
• Participant has a history of lack of response to > 1 therapeutic agent targeting tumor necrosis factor.
• Participant has received infliximab, golimumab, adalimumab, or certolizumab pegol, or any biosimilar of these agents, within 8 weeks prior to baseline (Day 1).
• Participant has received etanercept, or any biosimilar of etanercept, within 4 weeks prior to baseline (Day 1).
• Participant has received rituximab or any immune-cell-depleting therapy within 6 months prior to baseline (Day 1).
• Participant is currently receiving a non-biological investigational product or device or has received one within 4 weeks prior to baseline (Day 1).
• Participant has received apremilast or other non-biologic systemic treatment for PsA within 4 weeks prior to baseline (Day 1), other than methotrexate (MTX), sulfasalazine, corticosteroids, NSAIDs, or paracetamol/acetaminophen, which are allowed at stable doses as described in Inclusion Criterion 7. For participants not receiving MTX and sulfasalazine at screening, MTX and sulfasalazine are excluded within 4 weeks prior to baseline (Day 1). Participant has received leflunomide within 8 weeks of baseline (Day 1) if no elimination procedure was followed or adhere to an elimination procedure. For participants not receiving MTX and sulfasalazine at Screening, MTX and sulfasalazine are excluded within 4 weeks prior to baseline (Day 1).
• Participant has received intraarticular injection (including corticosteroids), intramuscular steroids, intralesional steroids, or intravenous steroids within 4 weeks prior to baseline (Day 1). For participants not receiving MTX and sulfasalazine at screening, MTX and sulfasalazine are excluded within 4 weeks prior to baseline (Day 1). For participants not receiving MTX and sulfasalazine at screening, MTX and sulfasalazine are excluded within 4 weeks prior to baseline (Day 1).
• Participant has received high potency opioid analgesics (eg, methadone, hydromorphone, or morphine) within 2 weeks prior to baseline (Day 1).
• Participant has used any topical medication that could affect PsA or psoriasis (including corticosteroids, retinoids, vitamin D analogues (such as calcipotriol), JAK inhibitors, or tar) within 2 weeks prior to baseline (Day 1).
• Participant has used any systemic treatment that could affect PsA or psoriasis (including oral retinoids, immunosuppressive/immunomodulating medication, cyclosporine, oral JAK inhibitors, or apremilast) within 4 weeks prior to baseline (Day 1).
• Participant has received any ultraviolet (UV)-B phototherapy (including tanning beds) or excimer laser within 4 weeks prior to baseline (Day 1).
• Participant has had psoralen and UV A (PUVA) treatment within 4 weeks prior to baseline (Day 1).
• Participant has received Chinese traditional medicine within 4 weeks prior to baseline (Day 1)
• Participant has received any live-attenuated vaccine, including for COVID-19, within 4 weeks prior to baseline (Day 1) or plans to receive a live-attenuated vaccine during the study and up to 4 weeks or 5 half-lives of the study drug, whichever is longer, after the last study drug administration.
• Participant is currently being treated with strong or moderate cytochrome P450 3A (CYP3A4) inhibitors, such as itraconazole or has received moderate or strong CYP3A4 inhibitors within 4 weeks prior to baseline (Day 1).
• Participant has consumed grapefruit or grapefruit juice within 1 week prior to baseline (Day 1).
• Participant has used tanning booths within 4 weeks prior to baseline (Day 1), has had excessive sun exposure, or is not willing to minimize natural and artificial sunlight exposure during the study.
• Participant is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study.
• Participant has evidence of erythrodermic, pustular, predominantly guttate psoriasis, or drug-induced psoriasis.
• Participant has any clinically significant medical condition, evidence of an unstable clinical condition, psychiatric condition, or vital signs/physical/laboratory/ECG abnormality that would, in the opinion of the investigator, put the participant at undue risk or interfere with interpretation of study results.
• Participant had a major surgery within 8 weeks prior to baseline (Day 1 or has a major surgery planned during the study.
• Participant has a history of Class III or IV congestive heart failure as defined by New York Heart Association Criteria.
• Participant has an estimated creatinine clearance of < 40 mL/min based on the Cockcroft-Gault equation or a history of renal failure.
• Participant was hospitalized in the 3 months prior to screening for asthma, has ever required intubation for treatment of asthma, currently require oral corticosteroids for the treatment of asthma, or has required more than one short-term (≤ 2 weeks) course of oral corticosteroids for asthma within 6 months prior to baseline (Day 1).
• Participant has a history of cancer or lymphoproliferative disease within 5 years prior to baseline (Day 1). Participants with successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix are not to be excluded.
• Participant has a history of fever, inflammation, or systemic signs of illness suggestive of systemic or invasive infection within 4 weeks prior to baseline (Day 1).
• Participant has an active bacterial, viral, fungal, mycobacterial infection, or other infection (including TB or atypical mycobacterial disease), or any major episode of infection that required hospitalization or treatment with intravenous antibiotics within 12 weeks prior to baseline (Day 1), or oral antibiotics within 4 weeks prior to baseline (Day 1).
• Participant has a history of chronic or recurrent infectious disease, including but not limited to chronic renal infection, chronic chest infection, recurrent urinary tract infection, fungal infection (with the exception of superficial fungal infection of the nailbed), or infected skin wounds or ulcers.
• Participant has a history of an infected joint prosthesis or has received antibiotics for a suspected infection of a joint prosthesis, if that prosthesis has not been removed or replaced.
• Participant has active herpes infection, including herpes simplex 1 and 2 and herpes zoster within 8 weeks prior to Day 1.
• Participant has a history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the Participant's immune status (eg, history of splenectomy, primary immunodeficiency).
• Participant has positive results for hepatitis B surface antigens (HBsAg), antibodies to hepatitis B core antigens (anti-HBc), hepatitis C virus (HCV), or human immunodeficiency virus (HIV). Samples testing positive for HCV antibodies will require polymerase chain reaction (PCR) qualitative testing for HCV RNA.
• Participant has clinical or laboratory evidence of active or latent TB infection at screening as assessed by QuantiFERON-TB Gold (or a purified protein derivative [PPD] skin test or equivalent, or both if required per local guidelines) and chest X-ray. The PPD skin test should be utilized only when a QuantiFERON-TB Gold Test is not possible for any reason (unless local guidelines require both tests). Chest X-ray may be taken at screening or completed within 3 months prior to the screening visit, with documentation showing no evidence of infection or malignancy as read by a qualified physician.
• Participant has a known or suspected allergy to NDI-034858 or any component of the investigational product, or any other significant drug allergy (such as anaphylaxis or hepatotoxicity).
• Participant has a known history of clinically significant drug or alcohol abuse in the last year prior to baseline (Day 1).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Nimbus Lakshmi, Inc.

INDUSTRY

Sponsor Role: collaborator

Takeda

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director

Role: STUDY_DIRECTOR

Takeda

Locations

Nimbus site #XYZ

Palm Desert, California, United States

Nimbus site #XYZ

Upland, California, United States

Nimbus site #XYZ

Hollywood, Florida, United States

Nimbus site #XYZ

Plantation, Florida, United States

Nimbus site #XYZ

St. Petersburg, Florida, United States

Nimbus site #XYZ

Tampa, Florida, United States

Nimbus site #XYZ

Tampa, Florida, United States

Nimbus site #XYZ

Winter Park, Florida, United States

Nimbus site #XYZ

Zephyrhills, Florida, United States

Nimbus site #XYZ

Indianapolis, Indiana, United States

Nimbus site #XYZ

West Des Moines, Iowa, United States

Nimbus site #XYZ

Lake Charles, Louisiana, United States

Nimbus site #XYZ

Worcester, Massachusetts, United States

Nimbus site #XYZ

Albuquerque, New Mexico, United States

Nimbus site #XYZ

Charlotte, North Carolina, United States

Nimbus site #XYZ

Duncansville, Pennsylvania, United States

Nimbus site #XYZ

Columbia, South Carolina, United States

Nimbus site #XYZ

Jackson, Tennessee, United States

Nimbus site #XYZ

Baytown, Texas, United States

Nimbus site #XYZ

Corpus Christi, Texas, United States

Nimbus site #XYZ

Houston, Texas, United States

Nimbus site #XYZ

Mesquite, Texas, United States

Nimbus site #XYZ

Beckley, West Virginia, United States

Nimbus site #XYZ

Hlučín, Ostrava-město, Czechia

Nimbus site #XYZ

Prague, Praha 3, Czechia

Nimbus site #XYZ

Ostrava, , Czechia

Nimbus site #XYZ

Pardubice, , Czechia

Nimbus site #XYZ

Uherské Hradiště, , Czechia

Nimbus site #XYZ

Zlín, , Czechia

Nimbus site #XYZ

Cottbus, Brandenburg, Germany

Nimbus site #XYZ

Bonn, North Rhine-Westphalia, Germany

Nimbus site #XYZ

Cologne, North Rhine-Westphalia, Germany

Nimbus site #XYZ

Herne, North Rhine-Westphalia, Germany

Nimbus site #XYZ

Ratingen, North Rhine-Westphalia, Germany

Nimbus site #XYZ

Berlin, , Germany

Nimbus site #XYZ

Berlin, , Germany

Nimbus site #XYZ

Hamburg, , Germany

Nimbus site #XYZ

Hamburg, , Germany

Nimbus site #XYZ

Krakow, Lesser Poland Voivodeship, Poland

Nimbus site #XYZ

Lublin, Lublin Voivodeship, Poland

Nimbus site #XYZ

Elblag, Warmian-Masurian Voivodeship, Poland

Nimbus site #XYZ

Bialystok, , Poland

Nimbus site #XYZ

Bydgoszcz, , Poland

Nimbus site #XYZ

Krakow, , Poland

Nimbus site #XYZ

Krakow, , Poland

Nimbus site #XYZ

Nadarzyn, , Poland

Nimbus site #XYZ

Nowa Sól, , Poland

Nimbus site #XYZ

Poznan, , Poland

Nimbus site #XYZ

Poznan, , Poland

Nimbus site #XYZ

Poznan, , Poland

Nimbus site #XYZ

Poznan, , Poland

Nimbus site #XYZ

Sochaczew, , Poland

Nimbus site #XYZ

Torun, , Poland

Nimbus site #XYZ

Warsaw, , Poland

Nimbus site #XYZ

Wroclaw, , Poland

Nimbus site #XYZ

Wroclaw, , Poland

Countries

United States; Czechia; Germany; Poland

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

https://clinicaltrials.takeda.com/study-detail/dcef5a65f54b4529

To obtain more information on the study, click here/on this link

Other Identifiers

2021-005888-52

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

4858-202

Identifier Type: -

Identifier Source: org_study_id